Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$NILIF bullish here: Surge Battery Metals is about to start phase 2 drilling on the Nevada North Lithium Project to expand its initial 8 hole discovery https://www.tgd8hjs.com/3J67C1/4THFX9F/
$GPHOF Graphite One Inc. (OTCQX: GPHOF) may be being driven by several key factors that are attracting a lot of attention. The company’s Graphite Creek Project, which boasts an impressive reserve of over 10 million metric tons of graphite with 7.8 percent graphite content, has the potential to transform the graphite market in the United States. Moreover, the completion of a positive Pre Feasibility Study (PFS) in Q2 2022 further reinforced confidence in the feasibility and potential of the Graphite Creek project
https://www.tgd8hjs.com/3J67C1/4TG32JS/
$GPHOF Graphite One Inc. (TSXV: GPH) (OTCQX: GPHOF)’s project has the potential to contribute to the domestic supply of graphite, supporting the growing demand for this essential mineral in the green energy transition
$NILIF The Inflation Reduction Act focuses on Battery Metal Exploration in North America to reduce U.S. dependence on foreign sources
https://www.tgd8hjs.com/3J67C1/4THFX9F/
$AMIH News: American International Holdings, Corp. Receives Funding Commitment of Up To $20 Million as an Initial Step in a Comprehensive Plan To Recapitalize The Company and Pursue Uplisting to a Major Exchange
Electra, Texas, July 17, 2023 (GLOBE NEWSWIRE) -- American International Holdings, Corp. (OTCQB: AMIH) announced today that it has entered into an Equity Financing Agreement with Pacific Lion LLC (Pacific Lion) pursuant to which Pacific Lion agreed to purchase up to $20,000,000 of AMIH common stock. Pacific Lion also agreed to fund AMIH up to $400,000 under a Convertible Promissory Note to bridge AMIH through to the effectiveness of the registration of the shares to be sold under the Equity Financing Agreement.
Pursuant to the Equity Financing Agreement, Pacific Lion has agreed to purchase up to $20,000,000 of AMIH common stock following the receipt of put notices from AMIH and subject to certain conditions. Pursuant to the Registration Rights Agreement entered into in connection with the Equity Financing Agreement, AMIH agreed to file a registration statement to register the common stock issuable under the Equity Financing Agreement. Following the effectiveness of the registration statement, if AMIH elects to cause Pacific Lion to purchase shares, the shares will be purchased at a 15% discount to the lowest closing trade price of AMIH's common stock in the prior 10 trading days. The Equity Financing Agreement with Pacific Lion replaces the Equity Financing Agreement previously entered into with GHS Investments LLC, which has been terminated.
Pursuant to the Convertible Promissory Note issued to Pacific Lion by AMIH, Pacific Lion has the right to fund up to $400,000. The note bears interest at 6% and is due on May 23, 2024. Following an uplisting to a senior stock exchange, the note will automatically convert at 80% of the uplisting offering price. In addition to the note, the Company also issued a Warrant to Purchase Shares of Common Stock to Pacific Lion. The warrant is exercisable for 500,000 shares for a period of five years at $0.10 per share. In the event that an uplisting to a senior stock exchange does not occur within nine months of the issuance date, the warrant will automatically be canceled. The note is designed to provide a mechanism for Pacific Lion to make regular fundings to cover AMIH's working capital needs during the pendency of the registration statement. Pacific Lion funded the first tranche of $100,000 upon the issuance of the note.
The proceeds will be used for general business operations. More information regarding the transaction will be provided in a Form 8-K to be filed with the SEC.
These investments are part of a broader restructuring plan to recapitalize the company, consolidate and retire existing debt and reduce dilution. This restructuring is designed to drive shareholder value and strengthen the balance sheet of the company.
"AMIH is executing on its core energy production operations, and we are ready to drive forward to scaling our revenues through expanded oil and gas production and property acquisitions as well as implementing the companies state of the art energy technologies.," said Michael McLaren, CEO of AMIH. "The capitalization of the company is critical, along with a comprehensive restructuring of debt and share classes, as well as reducing dilution in an effort to drive value for shareholders and prepare the company for uplisting to a major exchange."
In addition to the investment made by Pacific Lion in AMIH, the company will also be working with Pacific Lion, a firm that specializes in delivering strategic direct investments and hands-on advisory services to help with the growth of early-stage companies. The firm focuses on strategies that help capitalize public companies via retail and institutional investors, along with crowdfunding, equity lines and M+A consulting, with the goal of direct up listing to a major exchange over a 6-18-month targeted time frame.
"We believe that AMIH has developed an innovative approach to legacy oil & gas production combined with a keen focus on responsible energy production and social governance (ESG)," said Jacob Fernane, CEO of Pacific Lion. "We believe our access to strategic funding, share structure cleanup, technology and operations augmentation, and more, will allow AMIH to scale to the levels needed for a major exchange uplist and to rejuvenate its powerful energy-based business plan."
Another funding strategy the company intends to employ is to file an offering under Regulation A+. Regulation A+ allows companies to raise money under two different tiers. Fully reporting SEC reporting companies such as AMIH are able to raise up to $75,000,000 on a Tier 2 offering in any 12-month period from the general public. The company hopes to attract a new shareholder base and would like to help fund the company directly.
The company will continue in its efforts to secure additional funding and reduce debt in preparation for its attempts to uplist to a major exchange in the future.
About American International Holdings Corp.
American International Holdings Corp. (OTCQB: AMIH) is an investor, developer and asset manager diversified across multiple sectors, with a focus on the energy supply chain. As of the date of this release, the AMIH portfolio includes Cycle Energy Corp., a diversified energy company based in the state of Texas that currently owns and operates three vertically integrated businesses - Cycle Oil and Gas, Cycle Energy Services and Cycle Energy Technologies.
About Cycle Energy Corp.
Cycle Energy Corp. is an energy company based in the state of Texas and currently operates three vertically integrated businesses.
Cycle Oil and Gas. This wholly owned Texas subsidiaryfocuses on acquiring and optimizing underdeveloped oil and gas assets. It employs both internally developed and third party-licensed technologies to increase production, optimize performance and reduce costs. Cycle Oil and Gas currently produces approximately 25 barrels of oil per day from 16 leases on approximately 2,000 acers. The company currently has 125 wells on lease to reactivate. Since acquiring the leases in July 2022, Cycle Oil and Gas has increased production from an average of 7 barrels/day to 25 barrels per day. After reviewing well control data in the area, Cycle Oil and Gas believes that there is more recoverable oil available on these leases.
Cycle Energy Services. This wholly owned Texas subsidiary supports Cycle Energy's overall exploration and production efforts with "well services" and "end of life reclamation." Cycle Energy Services owns and operates a combination of customized service-wireline rigs and HydroVac units. This cutting-edge equipment allows for faster "rig in" and "rig out" times. Overall, Cycle Energy Services' equipment and experience combination seeks to reduce the amount of time and fuel burned to complete an abandonment or workover thus reducing costs.
Cycle Energy Technologies. This wholly owned Texas subsidiary provides both R&D and existing technology to enable increased production in the field. Cycle Energy's flagship intellectual property is its mobile Gas to Liquid system. This is used to convert natural gas and other gaseous hydrocarbons into longer-chain hydrocarbons, such as gasoline or diesel fuel.
Each of Cycle Energy's three vertically integrated businesses operate in tandem to help Cycle Energy capture unique opportunities that often go untapped by the Company's competitors.
To learn more about AMIH., please see our Twitter page at https://twitter.com/CycleNRG.
Forward-Looking Statements
This press release may contain forward-looking statements, including information about management's view of the Company's future expectations, plans and prospects, within the meaning of the federal securities laws, including the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 (the "Act"). In particular, when used in the preceding discussion, the words "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," "likely," "will," "would" and variations of these terms and similar expressions, or the negative of these terms or similar expressions are intended to identify forward-looking statements within the meaning of the Act and such laws, and are subject to the safe harbor created by the Act and applicable laws. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company and its subsidiaries to be materially different than those expressed or implied in such statements. Forward-looking statements may include projections and estimates of the Company's corporate strategies, future operations, results of operations, development plans and programs, including the costs thereof, drilling locations, estimated oil, natural gas and natural gas liquids production, price realizations, projected operating, general and administrative and other costs, projected capital expenditures, efficiency and cost reduction initiative outcomes, statements regarding future production, costs and cash flows, liquidity and our capital structure. We have based these forward-looking statements on our current expectations and assumptions and analyses made by us in light of our experience and our perception of historical trends, current conditions and expected future developments, as well as other factors we believe are appropriate under the circumstances. However, whether actual results and developments will conform with our expectations and predictions is subject to a number of risks and uncertainties, including access to additional financing, and the potential lack of such financing; and the Company's ability to raise funding in the future and the terms of such funding; the volatility of oil and natural gas prices; our success in discovering, estimating, developing and replacing oil and natural gas reserves; risks of our operations not being profitable or generating sufficient cash flow to meet our obligations; risks relating to the future price of oil, natural gas and NGLs; risks related to the status and availability of oil and natural gas gathering, transportation, and storage facilities; risks related to changes in the legal and regulatory environment governing the oil and gas industry, and new or amended environmental legislation and regulatory initiatives; risks related to the need for additional capital to complete future acquisitions, conduct our operations, and fund our business on favorable terms, if at all, the availability of such funding and the costs thereof; risks related to the speculative nature of oil and gas operations; risks related to the Company maintaining and/or increasing production from prior periods, and the costs related thereto; risks associated with the uncertainty of drilling, completion and enhanced recovery operations; risks associated with illiquidity and volatility of our common stock, dependence upon present management, the fact that Michael McLaren, our CEO and member of the Board, beneficially owns a majority of our voting stock; COVID-19, governmental responses thereto, economic downturns and possible recessions caused thereby; inflationary risks and recent increased interest rates, and the risks of recessions and economic downturns caused thereby; risks related to military conflicts in oil producing countries; changes in economic conditions; limitations in the availability of, and costs of, supplies, materials, contractors and services that may delay the drilling or completion of wells or make such wells more expensive; the amount and timing of future development costs; the availability and demand for alternative energy sources; regulatory changes, including those related to carbon dioxide and greenhouse gas emissions; and others that are included from time to time in filings made by the Company with the Securities and Exchange Commission, many of which are beyond our control, including, but not limited to, in the "Risk Factors" sections in the Company's Form 10-Ks and Form 10-Qs and in its Form 8-Ks, which it has filed, and files from time to time, with the U.S. Securities and Exchange Commission. These reports are available at www.sec.gov. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.
Media contact:
Glass Box Agency
https://glassboxagency.com
info@glassboxagency.com
(844) 292-2722
$BRLL News: BARREL SAMPLES UP TO 2.5% LI2O AT TITAN X PROJECT, TANZANIA
Las Vegas, NV., July 12, 2023 (GLOBE NEWSWIRE) -- Barrel Energy Inc., (OTC Markets: BRLL) (the "Company" or "Barrel") is pleased to announce additional soil geochemical sampling results from prospecting a central portion of the company's Titan X lithium property in Tanzania.
The Titan X project is located directly south of, and adjacent to, the Titan 1 project of Titan Lithium Inc. Both Titan X and Titan 1 occur within a large northeast-southwest-striking rift valley that served to trap lithium-rich source volcanics and sediments in this area of the East African Rift.
The new samples were collected during our second phase of soil geochemical work a distance of up to 2.5 miles south of northern claim boundary. The newly covered area serves to further extend the Titan X sample coverage south of those reported previously in the Company news release dated June 13, 2023.
From the combined results, we note that positive Lithium geochemical values average now 3,985 ppm Lithium over a sampled area of approximately 2,400 acres. The highest value in the new sample set returned 11,600 ppm Li (2.5 % Li2O) which was located 0.7 miles (1.14km) west from the previous lithium high value in the first batch which was 6,100 ppm Li (1.32% Li2O).
Craig Alford, MSc, PGeo, a Qualified Person under NI 43-101 and CEO of the Company, noted "The new samples have extended the Titan X lithium anomaly to the south and this coverage now more than doubles the sampled area from our initial reported results. Our surficial lithium values continue to return extremely high values and we plan addition sampling in the west where we are observing the highest grades so far on the project."
All samples were collected and transported to the laboratory under the direct supervision of a qualified person. The soil samples were recovered from the B-soil horizon and placed in cloth sample bags. The samples were thoroughly dried at 60oC during preparation and analyzed at the independent and ISO 9001 certified African Minerals and Geosciences Centre (AMGC) in Dar es Salaam.
About Barrel: Barrel Energy Inc., (OTC Markets: BRLL) is focused on several ventures within the green energy and battery minerals sector and the rapid development of valuable production opportunities throughout North America and abroad. The company holds important joint venture agreements to advance technologies and processes for Electric Vehicle batteries.
Please visit our new website www.barrel.energy and our twitter www.twitter.com/barrelenergy for more updates.
Contact: Harp Sangha/Chairman
+17025952247/sanghaharp1964@gmail.com
Forward-Looking Statements:
This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company's business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company's periodic filings with the Security and Exchange Commission.
$MGRX sells high-quality, convenient, and affordable prescription ED medication - 100% online. With Mango, you're not just getting a prescription - you're joining a movement that's shaking up the men's health scene, one groundbreaking treatment at a time. https://www.mangorx.com
$AMIH News: American International Holdings Corp Shareholder update.
Electra, Texas, June 29, 2023 (GLOBE NEWSWIRE) -- American International Holdings Corp. (OTCQB: AMIH), ("AMIH" or the "Company"), a diversified holding company, is pleased to provide a shareholder update on ongoing corporate operations.
Integration Of Cycle Energy Corp.
On March 27th, 2023, AMIH announced that it had completed the acquisition of Cycle Energy Corp. a diversified energy company based in the state of Texas and currently operates three vertically integrated businesses. To date the team has been working tirelessly to integrate operations and financial information for reporting purposes. On June 9th, 2023, the outgoing team and incoming team worked seamlessly together to complete and file the 10K for 2022. The finance team is now nearing completion of the 10Q for 2023 which will have the integrated financial and business plan of Cycle Energy Corp. Management is excited to get this part of the transaction behind us and focus on the bright future ahead.
Oil production operations
The past few months the Electra production team has been focusing on maintaining the previously announced average production of approximately 500 barrels per month. The operations team has been working aggressively to bring on as much production while working within the constrained budget and cashflow while management restructures the company and positions the company to be able to raise capital to capitalize field operations. There are still approximately 120 wells that are available on our current leases that can be brought into production.
AcquisitionStrategy:
AMIH is currently looking at several possible "bolt on" properties to our existing leases as acquisition candidates. Now that integration of the companies is nearing completion management will begin to approach potential candidates in the area. Cycle oil and gas production operations are currently focused on Wichita and Wilbarger counties however intends to expand that focus through the area into neighboring counties.
Technologies:
Cycle continues to work on the development of its core technology. The company intends to ramp up development of the GTL project mid to late 2023. Other technologies will be revisited when the right project parameters arise and budget permits.
About American International Holdings Corp.
American International Holdings Corp. (OTCQB:AMIH) is an investor, developer and asset manager diversified across multiple sectors, with a focus on the energy supply chain. As of the date of this release, the AMIH portfolio includes Cycle Energy Corp., a diversified energy company based in the state of Texas that currently owns and operates three vertically integrated businesses - Cycle Oil and Gas, Cycle Energy Services and Cycle Energy Technologies.
About Cycle Energy Corp.
Cycle Energy Corp. is an energy company based in the state of Texas and currently operates three vertically integrated businesses.
Cycle Oil and Gas. This wholly-owned Texas subsidiaryfocuses on acquiring and optimizing underdeveloped oil and gas assets. It employs both internally developed and third party-licensed technologies to increase production, optimize performance and reduce costs. Cycle Oil and Gas currently produces approximately 25 barrels of oil per day from 16 leases on approximately 2,000 acers. The company currently has 125 wells on lease to reactivate. Since acquiring the leases in July 2022, Cycle Oil and Gas has increased production from an average of 7 barrels/day to 25 barrels per day. After reviewing well control data in the area, Cycle Oil and Gas believes that there is more recoverable oil available on these leases.
Cycle Energy Services. This wholly-owned Texas subsidiary supports Cycle Energy's overall exploration and production efforts with "well services" and "end of life reclamation." Cycle Energy Services owns and operates a combination of customized service-wireline rigs and HydroVac units. This cutting-edge equipment allows for faster "rig in" and "rig out" times. Overall, Cycle Energy Services equipment and experience combination seeks to reduce the amount of time and fuel burned to complete an abandonment or workover thus reducing costs.
Cycle Energy Technologies. This wholly owned Texas subsidiary provides both R&D and existing technology to enable increased production in the field. Cycle Energy's flagship intellectual property is its mobile Gas to Liquid system. This is used to convert natural gas and other gaseous hydrocarbons into longer-chain hydrocarbons, such as gasoline or diesel fuel.
Each of Cycle Energy's three vertically integrated businesses operate in tandem to help Cycle Energy capture unique opportunities that often go untapped by the Company's competitors. To learn more about Cycle Energy Corp., please see our Twitter page at https://twitter.com/CycleNRG.
Forward-Looking Statements
This press release may contain forward-looking statements, including information about management's view of the Company's future expectations, plans and prospects, within the meaning of the federal securities laws, including the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 (the "Act"). In particular, when used in the preceding discussion, the words "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," "likely," "will," "would" and variations of these terms and similar expressions, or the negative of these terms or similar expressions are intended to identify forward-looking statements within the meaning of the Act and such laws, and are subject to the safe harbor created by the Act and applicable laws. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company and its subsidiaries to be materially different than those expressed or implied in such statements. Forward-looking statements may include projections and estimates of the Company's corporate strategies, future operations, results of operations, development plans and programs, including the costs thereof, drilling locations, estimated oil, natural gas and natural gas liquids production, price realizations, projected operating, general and administrative and other costs, projected capital expenditures, efficiency and cost reduction initiative outcomes, statements regarding future production, costs and cash flows, liquidity and our capital structure. We have based these forward-looking statements on our current expectations and assumptions and analyses made by us in light of our experience and our perception of historical trends, current conditions and expected future developments, as well as other factors we believe are appropriate under the circumstances. However, whether actual results and developments will conform with our expectations and predictions is subject to a number of risks and uncertainties, including access to additional financing, and the potential lack of such financing; and the Company's ability to raise funding in the future and the terms of such funding; the volatility of oil and natural gas prices; our success in discovering, estimating, developing and replacing oil and natural gas reserves; risks of our operations not being profitable or generating sufficient cash flow to meet our obligations; risks relating to the future price of oil, natural gas and NGLs; risks related to the status and availability of oil and natural gas gathering, transportation, and storage facilities; risks related to changes in the legal and regulatory environment governing the oil and gas industry, and new or amended environmental legislation and regulatory initiatives; risks related to the need for additional capital to complete future acquisitions, conduct our operations, and fund our business on favorable terms, if at all, the availability of such funding and the costs thereof; risks related to the speculative nature of oil and gas operations; risks related to the Company maintaining and/or increasing production from prior periods, and the costs related thereto; risks associated with the uncertainty of drilling, completion and enhanced recovery operations; risks associated with illiquidity and volatility of our common stock, dependence upon present management, the fact that Michael McLaren, our CEO and member of the Board, beneficially owns a majority of our voting stock; COVID-19, governmental responses thereto, economic downturns and possible recessions caused thereby; inflationary risks and recent increased interest rates, and the risks of recessions and economic downturns caused thereby; risks related to military conflicts in oil producing countries; changes in economic conditions; limitations in the availability of, and costs of, supplies, materials, contractors and services that may delay the drilling or completion of wells or make such wells more expensive; the amount and timing of future development costs; the availability and demand for alternative energy sources; regulatory changes, including those related to carbon dioxide and greenhouse gas emissions; and others that are included from time to time in filings made by the Company with the Securities and Exchange Commission, many of which are beyond our control, including, but not limited to, in the "Risk Factors" sections in the Company's Form 10-Ks and Form 10-Qs and in its Form 8-Ks, which it has filed, and files from time to time, with the U.S. Securities and Exchange Commission. These reports are available at www.sec.gov. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.
Media contact:
Glass Box Agency
https://glassboxagency.com
info@glassboxagency.com
(844) 292-2722
$LPTV $MMMW large upside potential.
$LPTV B. Riley Securities Initiates Coverage on Loop Media, Inc. (NYSE American: LPTV) with a $5.00 Target
$AITX's Subsidiary, Robotic Assistance Devices, to Host 'Police Day' July 13, 2023, Featuring Demonstrations of RADDOG(TM)
Detroit, Michigan, June 27, 2023 (GLOBE NEWSWIRE) -- Artificial Intelligence Technology Solutions, Inc., (the "Company") (OTCPK:AITX), a global leader in AI-driven security and productivity solutions along with its wholly owned subsidiary, Robotic Assistance Devices, Inc. (RAD), today announced that it will be hosting 'Police Day', a hands-on event for law enforcement agencies and first responders. The event will be held at the Company's manufacturing facility, the 'REX', located in Ferndale, Michigan on Thursday July 13, 2023, from 10:00am to 11:30am ET.
The event is meant to showcase the RADDOG family of robots to area law enforcement personnel that may be considering adding advanced robotics to their force. RAD recently announced that it is taking pre-orders for RADDOG 2LE, specifically designed for law enforcement applications. RADDOG 2LE is a critical evolution of quadruped robotics positioned to improve the capabilities of law enforcement agencies and enable them to apply practical robotics for a variety of tasks. With its agile quadruped (four-legged) design and cutting-edge external accessories, RADDOG 2LE empowers officers to conquer challenging terrain, reach inaccessible areas, and navigate through dangerous environments.
RAD is also expected to introduce RADDOG 1LE at the Police Day event. This unit includes RAD's RADPack(TM) on a smaller quadruped and will have an entry-level price point that is expected to be accessible to most law enforcement agencies.
Troy McCanna, RAD's Chief Security Officer and a former FBI Agent with extensive experience as a Multi-Jurisdictional Task Force Coordinator/Supervisor, commented on the event, "RADDOG is the force-multiplier that I wish I had by my side during my time in service. At the Police Day event, I look forward to presenting RADDOG to my former colleagues. Their early response to the dog's availability has been overwhelming. Now they'll have a chance to see it up close and even operate it."
Detroit area law enforcement agencies and other first responders are encouraged to attend. To register for the event, please visit www.tinyurl.com/hts36w5r. The event is closed to the public, only approved registered guests may attend.
The RADDOG quadruped (dog-style) robots used in the show are similar to RADDOG 2LE units. The "Stars on Mars" RADDOGs perform the duties of the mission's security robots, executing field reconnaissance and surveillance, as well as being companions to the crew members.
RAD's proprietary RADPack on RADDOG 2LE, and the highly anticipated RADDOG 1LE, offers unique features, specifically including an interactive touch screen located at the front of the quadruped. This interface facilitates smooth, high-definition video communication between remote law enforcement officers and individuals within the robot's vicinity. Complemented by integrated microphones, powerful audio speakers, and front headlights, the RADDOG family of robots for law enforcement possesses an array of capabilities to effectively engage with and capture the attention of those it may confront.
"I am so proud of all that we've designed into RADDOG that I can't wait to present it to our esteemed guests at Police Day," said Steve Reinharz, CEO of AITX and RAD. "We are planning on making this an amazing event where law enforcement personnel can fully review all of RADDOG's capabilities, features and costs and be in the position to place their initial orders."
RADDOG 2LE is scheduled to begin shipping in late July. Complete specifics of its capabilities, features and other details can be found at www.raddog.ai and www.radsecurity.com.
AITX, through its subsidiary, Robotic Assistance Devices, Inc. (RAD), is redefining the $25 billion (US) security and guarding services industry through its broad lineup of innovative, AI-driven Solutions-as-a-Service business model. RAD solutions are specifically designed to provide cost savings to businesses of between 35%-80% when compared to the industry's existing and costly manned security guarding and monitoring model. RAD delivers this tremendous cost savings via a suite of stationary and mobile robotic solutions that complement, and at times, directly replace the need for human personnel in environments better suited for machines. All RAD technologies, AI-based analytics and software platforms are developed in-house.
RAD has a prospective sales pipeline of over 35 Fortune 500 companies and numerous other client opportunities. RAD expects to continue to attract new business as it converts its existing sales opportunities into deployed clients generating a recurring revenue stream. Each Fortune 500 client has the potential of making numerous reorders over time.
CAUTIONARY DISCLOSURE ABOUT FORWARD-LOOKING STATEMENTS
The information contained in this publication does not constitute an offer to sell or solicit an offer to buy securities of Artificial Intelligence Technology Solutions, Inc. (the "Company"). This publication contains forward-looking statements, which are not guarantees of future performance and may involve subjective judgment and analysis. The information provided herein is believed to be accurate and reliable, however the Company makes no representations or warranties, expressed or implied, as to its accuracy or completeness. The Company has no obligation to provide the recipient with additional updated information. No information in this publication should be interpreted as any indication whatsoever of the Company's future revenues, results of operations, or stock price.
About Artificial Intelligence Technology Solutions (AITX)
AITX is an innovator in the delivery of artificial intelligence-based solutions that empower organizations to gain new insight, solve complex challenges and fuel new business ideas. Through its next-generation robotic product offerings, AITX's RAD, RAD-M and RAD-G companies help organizations streamline operations, increase ROI, and strengthen business. AITX technology improves the simplicity and economics of patrolling and guard services and allows experienced personnel to focus on more strategic tasks. Customers augment the capabilities of existing staff and gain higher levels of situational awareness, all at drastically reduced cost. AITX solutions are well suited for use in multiple industries such as enterprises, government, transportation, critical infrastructure, education, and healthcare. To learn more, visit http://www.aitx.ai, http://www.radsecurity.com,http://www.stevereinharz.com, http://www.radgroup.ai, http://www.raddog.ai, and http://www.radlightmyway.com, or follow Steve Reinharz on Twitter @SteveReinharz.
###
Steve Reinharz
949-636-7060
@SteveReinharz
$MGRX on alert, check out the video: HUGE CATALYST DROPPED!
$MGRX - There are some really funny videos on the MangoRx YouTube channel
https://www.youtube.com/@mango_rx
$MMMW and $AITX useful great recent new tech developments. $MMMW only 152 million shares.
$KRTL Medflow, an AI-powered telemedicine solution provider, combines best-in-class facial recognition biometrics with next-generation zero-trust security architecture to accurately verify patient identities. Their comprehensive suite of telemedicine tools, designed with security at the forefront, includes features like end-to-end encryption, facial recognition with ID scan, and HIPAA compliance. The platform allows healthcare providers to review and legally sign medical and legal documentation live with the patient, issue prescriptions, and capture patient vitals such as heart rate, blood pressure, breathing, and stress indicators, all using the patient's computer or mobile phone camera.
https://www.marketwatch.com/press-release/krtl-partnered-to-bring-comprehensive-cloud-and-endpoint-security-and-ai-powered-telemedicine-solutions-2023-05-30?mod=mw_quote_news_seemore
$KRTL pioneer in developing industry-leading cross-over tradecraft and proprietary technology in the hemp, cannabis, psilocybin, and alternative wellness sectors, announces that its wholly owned subsidiary, KRTL Biotech (“KRTL”), has entered into a channel partner agreement and white label contract with Medflow Inc. (“Medflow”), creator of a cutting-edge computer-vision based telemedicine platform. This exclusive contract allows KRTL to use and apply Medflow's innovative telemedicine technology in the alternative wellness market.
Medflow, an AI-powered telemedicine solution provider, combines best-in-class facial recognition biometrics with next-generation zero-trust security architecture to accurately verify patient identities. Their comprehensive suite of telemedicine tools, designed with security at the forefront, includes features like end-to-end encryption, facial recognition with ID scan, and HIPAA compliance. The platform allows healthcare providers to review and legally sign medical and legal documentation live with the patient, issue prescriptions, and capture patient vitals such as heart rate, blood pressure, breathing, and stress indicators, all using the patient's computer or mobile phone camera.
Daniel Ball, CEO of KRTL Biotech, is excited about this partnership. He states, "Our collaboration with Medflow is a significant step forward in our mission to enhance patient care in the alternative wellness sector. The integration of Medflow's state-of-the-art telemedicine platform will allow us to provide secure and robust health-related services remotely in the alternative wellness market."
Kelly Fenemore, CEO of Medflow, also shares this enthusiasm. "We are thrilled to partner with KRTL Biotech, a company that shares our commitment to innovation and patient care. This partnership reinforces our mission to provide secure and accessible telemedicine services to patients everywhere."
In a strategic move to bolster its cybersecurity capabilities in support of their MedTech expansion, KRTL Biotech has also entered into a channel partner agreement with boutique cybersecurity firm, Seven Cipher Group LLC ("Seven Cipher"). Seven Cipher combines industry-leading technology and methodology to provide comprehensive cloud and endpoint security solutions. Their innovative approach includes AI, machine learning, and behavioral analytics for proactive threat detection and management.
Seven Cipher’s robust vulnerability assessment and management solutions, along with compliance standards such as ISO, NIST, GDPR, SOC2, and others, will ensure a multi-layered security and compliance approach for KRTL's operations. This partnership will enhance KRTL's ability to safeguard its client’s Web2 and Web3 environments from future threats, including AI-assisted intrusions and eventual quantum-based attacks.
Bryant Thornton, CEO of Seven Cipher, recognizes the significance of this alliance. "Our partnership with KRTL Biotech signals the accessibility and attainability of enterprise-level cybersecurity at a small and medium business level in the alternative wellness industry and beyond. With our combined expertise, we are well-positioned to tackle the unique challenges of this rapidly evolving digital landscape."
"Our partnership with Seven Cipher is crucial in our commitment to provide secure and reliable services in our MedTech efforts alongside solutions like Medflow. As we continue to innovate in our industry, the security of our operations and the privacy of our clients and partners remain a top priority." KRTL Biotech’s CEO, Daniel Ball added.
About KRTL Holding Group, Inc.
KRTL is a holding company interested in diversifying risk and accessing new markets. KRTL Holding Group Inc. operates its wholly owned subsidiaries, KRTL Biotech, Inc. and KRTL International Corp. Each company has its focus on specific industries including bio and Agri-Technology, to International Trade and Distribution of these technologies and services. This strategy allows KRTL Holding Group to capitalize on investment opportunities, and partnerships, creating value for its shareholders. Additional information on KRTL is available online at www.krtlholding.com and www.krtl-icc.com and www.krtlbiotech.com.
About Medflow Inc.
Medflow is a telemedicine company that offers a suite of secure and innovative telemedicine tools. Its offerings include facial recognition biometrics, zero-trust architecture, end-to-end encryption, and a variety of computer vision-based features. These tools allow healthcare providers to offer efficient and secure patient care. For more information about Medflow, visit www.medflow.com.
About Seven Cipher Group LLC
Seven Cipher Group LLC is a boutique cybersecurity firm that offers comprehensive security solutions designed for Web2 and Web3 environments. The company combines industry-leading technology and methodology to offer real-time, comprehensive analysis across your cloud and endpoint security landscape. Seven Cipher Group LLC is committed to proactively identifying and mitigating threats before they occur. For more information about Seven Cipher Group LLC, visit www.sevencipher.com.
$KRTL heading for a breakout, on alert this week! Huge News: Partnered to Bring Comprehensive Cloud and Endpoint Security and AI Powered Telemedicine Solutions https://finance.yahoo.com/news/krtl-partnered-bring-comprehensive-cloud-130000765.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
$KRTL on Twitter - https://twitter.com/KRTLHolding
$KRTL Medflow, an AI-powered telemedicine solution provider, combines best-in-class facial recognition biometrics with next-generation zero-trust security architecture to accurately verify patient identities. Their comprehensive suite of telemedicine tools, designed with security at the forefront, includes features like end-to-end encryption, facial recognition with ID scan, and HIPAA compliance. The platform allows healthcare providers to review and legally sign medical and legal documentation live with the patient, issue prescriptions, and capture patient vitals such as heart rate, blood pressure, breathing, and stress indicators, all using the patient's computer or mobile phone camera.
https://www.marketwatch.com/press-release/krtl-partnered-to-bring-comprehensive-cloud-and-endpoint-security-and-ai-powered-telemedicine-solutions-2023-05-30?mod=mw_quote_news_seemore
$KRTL Recent news can be found here https://www.krtlholding.com/news
$AITX Artificial Intelligence Technology Solutions (OTCPK:AITX) Reports Annual Results and Corporate Updates https://finance.yahoo.com/news/artificial-intelligence-technology-solutions-otcpk-124000826.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
$KRTL has entered into a channel partner agreement and white label contract with Medflow Inc. (“Medflow”), creator of a cutting-edge computer-vision based telemedicine platform. This exclusive contract allows KRTL to use and apply Medflow's innovative telemedicine technology in the alternative wellness market.
Medflow, an AI-powered telemedicine solution provider, combines best-in-class facial recognition biometrics with next-generation zero-trust security architecture to accurately verify patient identities. Their comprehensive suite of telemedicine tools, designed with security at the forefront, includes features like end-to-end encryption, facial recognition with ID scan, and HIPAA compliance. The platform allows healthcare providers to review and legally sign medical and legal documentation live with the patient, issue prescriptions, and capture patient vitals such as heart rate, blood pressure, breathing, and stress indicators, all using the patient's computer or mobile phone camera.
Daniel Ball, CEO of KRTL Biotech, is excited about this partnership. He states, "Our collaboration with Medflow is a significant step forward in our mission to enhance patient care in the alternative wellness sector. The integration of Medflow's state-of-the-art telemedicine platform will allow us to provide secure and robust health-related services remotely in the alternative wellness market."
Kelly Fenemore, CEO of Medflow, also shares this enthusiasm. "We are thrilled to partner with KRTL Biotech, a company that shares our commitment to innovation and patient care. This partnership reinforces our mission to provide secure and accessible telemedicine services to patients everywhere."
In a strategic move to bolster its cybersecurity capabilities in support of their MedTech expansion, KRTL Biotech has also entered into a channel partner agreement with boutique cybersecurity firm, Seven Cipher Group LLC ("Seven Cipher"). Seven Cipher combines industry-leading technology and methodology to provide comprehensive cloud and endpoint security solutions. Their innovative approach includes AI, machine learning, and behavioral analytics for proactive threat detection and management.
Seven Cipher’s robust vulnerability assessment and management solutions, along with compliance standards such as ISO, NIST, GDPR, SOC2, and others, will ensure a multi-layered security and compliance approach for KRTL's operations. This partnership will enhance KRTL's ability to safeguard its client’s Web2 and Web3 environments from future threats, including AI-assisted intrusions and eventual quantum-based attacks.
Bryant Thornton, CEO of Seven Cipher, recognizes the significance of this alliance. "Our partnership with KRTL Biotech signals the accessibility and attainability of enterprise-level cybersecurity at a small and medium business level in the alternative wellness industry and beyond. With our combined expertise, we are well-positioned to tackle the unique challenges of this rapidly evolving digital landscape."
"Our partnership with Seven Cipher is crucial in our commitment to provide secure and reliable services in our MedTech efforts alongside solutions like Medflow. As we continue to innovate in our industry, the security of our operations and the privacy of our clients and partners remain a top priority." KRTL Biotech’s CEO, Daniel Ball added.
About KRTL Holding Group, Inc.
KRTL is a holding company interested in diversifying risk and accessing new markets. KRTL Holding Group Inc. operates its wholly owned subsidiaries, KRTL Biotech, Inc. and KRTL International Corp. Each company has its focus on specific industries including bio and Agri-Technology, to International Trade and Distribution of these technologies and services. This strategy allows KRTL Holding Group to capitalize on investment opportunities, and partnerships, creating value for its shareholders. Additional information on KRTL is available online at www.krtlholding.com and www.krtl-icc.com and www.krtlbiotech.com.
$KRTL (GLOBE NEWSWIRE) -- KRTL Holding Group, Inc. (OTC:KRTL), an innovator and pioneer in developing industry-leading cross-over tradecraft and proprietary technology in the hemp, cannabis, psilocybin, and alternative wellness sectors, announces that its wholly owned subsidiary, KRTL Biotech (“KRTL”), has entered into a channel partner agreement and white label contract with Medflow Inc. (“Medflow”), creator of a cutting-edge computer-vision based telemedicine platform. This exclusive contract allows KRTL to use and apply Medflow's innovative telemedicine technology in the alternative wellness market.
Medflow, an AI-powered telemedicine solution provider, combines best-in-class facial recognition biometrics with next-generation zero-trust security architecture to accurately verify patient identities. Their comprehensive suite of telemedicine tools, designed with security at the forefront, includes features like end-to-end encryption, facial recognition with ID scan, and HIPAA compliance. The platform allows healthcare providers to review and legally sign medical and legal documentation live with the patient, issue prescriptions, and capture patient vitals such as heart rate, blood pressure, breathing, and stress indicators, all using the patient's computer or mobile phone camera.
Daniel Ball, CEO of KRTL Biotech, is excited about this partnership. He states, "Our collaboration with Medflow is a significant step forward in our mission to enhance patient care in the alternative wellness sector. The integration of Medflow's state-of-the-art telemedicine platform will allow us to provide secure and robust health-related services remotely in the alternative wellness market."
Kelly Fenemore, CEO of Medflow, also shares this enthusiasm. "We are thrilled to partner with KRTL Biotech, a company that shares our commitment to innovation and patient care. This partnership reinforces our mission to provide secure and accessible telemedicine services to patients everywhere."
In a strategic move to bolster its cybersecurity capabilities in support of their MedTech expansion, KRTL Biotech has also entered into a channel partner agreement with boutique cybersecurity firm, Seven Cipher Group LLC ("Seven Cipher"). Seven Cipher combines industry-leading technology and methodology to provide comprehensive cloud and endpoint security solutions. Their innovative approach includes AI, machine learning, and behavioral analytics for proactive threat detection and management.
Seven Cipher’s robust vulnerability assessment and management solutions, along with compliance standards such as ISO, NIST, GDPR, SOC2, and others, will ensure a multi-layered security and compliance approach for KRTL's operations. This partnership will enhance KRTL's ability to safeguard its client’s Web2 and Web3 environments from future threats, including AI-assisted intrusions and eventual quantum-based attacks.
Bryant Thornton, CEO of Seven Cipher, recognizes the significance of this alliance. "Our partnership with KRTL Biotech signals the accessibility and attainability of enterprise-level cybersecurity at a small and medium business level in the alternative wellness industry and beyond. With our combined expertise, we are well-positioned to tackle the unique challenges of this rapidly evolving digital landscape."
"Our partnership with Seven Cipher is crucial in our commitment to provide secure and reliable services in our MedTech efforts alongside solutions like Medflow. As we continue to innovate in our industry, the security of our operations and the privacy of our clients and partners remain a top priority." KRTL Biotech’s CEO, Daniel Ball added.
About KRTL Holding Group, Inc.
KRTL is a holding company interested in diversifying risk and accessing new markets. KRTL Holding Group Inc. operates its wholly owned subsidiaries, KRTL Biotech, Inc. and KRTL International Corp. Each company has its focus on specific industries including bio and Agri-Technology, to International Trade and Distribution of these technologies and services. This strategy allows KRTL Holding Group to capitalize on investment opportunities, and partnerships, creating value for its shareholders. Additional information on KRTL is available online at www.krtlholding.com and www.krtl-icc.com and www.krtlbiotech.com.
$KRTL In a strategic move to bolster its cybersecurity capabilities in support of their MedTech expansion, KRTL Biotech has also entered into a channel partner agreement with boutique cybersecurity firm, Seven Cipher Group LLC ("Seven Cipher"). Seven Cipher combines industry-leading technology and methodology to provide comprehensive cloud and endpoint security solutions. Their innovative approach includes AI, machine learning, and behavioral analytics for proactive threat detection and management.
https://www.morningstar.com/news/globe-newswire/8847936/krtl-partnered-to-bring-comprehensive-cloud-and-endpoint-security-and-ai-powered-telemedicine-solutions
$MGRX invites all shareholders and MangoRx customers to their Youtube channel and view the Official MangoRX commercial, as they also prepare to Nationally launch commercials on major cable television stations. https://www.youtube.com/@mango_rx/videos
$KRTL Recent news can be found here https://www.krtlholding.com/news
$KRTL Kelly Fenemore, CEO of Medflow, also shares this enthusiasm. "We are thrilled to partner with KRTL Biotech, a company that shares our commitment to innovation and patient care. This partnership reinforces our mission to provide secure and accessible telemedicine services to patients everywhere."
In a strategic move to bolster its cybersecurity capabilities in support of their MedTech expansion, KRTL Biotech has also entered into a channel partner agreement with boutique cybersecurity firm, Seven Cipher Group LLC ("Seven Cipher"). Seven Cipher combines industry-leading technology and methodology to provide comprehensive cloud and endpoint security solutions. Their innovative approach includes AI, machine learning, and behavioral analytics for proactive threat detection and management.
Seven Cipher’s robust vulnerability assessment and management solutions, along with compliance standards such as ISO, NIST, GDPR, SOC2, and others, will ensure a multi-layered security and compliance approach for KRTL's operations. This partnership will enhance KRTL's ability to safeguard its client’s Web2 and Web3 environments from future threats, including AI-assisted intrusions and eventual quantum-based attacks.
Bryant Thornton, CEO of Seven Cipher, recognizes the significance of this alliance. "Our partnership with KRTL Biotech signals the accessibility and attainability of enterprise-level cybersecurity at a small and medium business level in the alternative wellness industry and beyond. With our combined expertise, we are well-positioned to tackle the unique challenges of this rapidly evolving digital landscape."
"Our partnership with Seven Cipher is crucial in our commitment to provide secure and reliable services in our MedTech efforts alongside solutions like Medflow. As we continue to innovate in our industry, the security of our operations and the privacy of our clients and partners remain a top priority." KRTL Biotech’s CEO, Daniel Ball added.
About KRTL Holding Group, Inc.
KRTL is a holding company interested in diversifying risk and accessing new markets. KRTL Holding Group Inc. operates its wholly owned subsidiaries, KRTL Biotech, Inc. and KRTL International Corp. Each company has its focus on specific industries including bio and Agri-Technology, to International Trade and Distribution of these technologies and services. This strategy allows KRTL Holding Group to capitalize on investment opportunities, and partnerships, creating value for its shareholders. Additional information on KRTL is available online at www.krtlholding.com and www.krtl-icc.com and www.krtlbiotech.com.
About Medflow Inc.
Medflow is a telemedicine company that offers a suite of secure and innovative telemedicine tools. Its offerings include facial recognition biometrics, zero-trust architecture, end-to-end encryption, and a variety of computer vision-based features. These tools allow healthcare providers to offer efficient and secure patient care. For more information about Medflow, visit www.medflow.com.
About Seven Cipher Group LLC
Seven Cipher Group LLC is a boutique cybersecurity firm that offers comprehensive security solutions designed for Web2 and Web3 environments. The company combines industry-leading technology and methodology to offer real-time, comprehensive analysis across your cloud and endpoint security landscape. Seven Cipher Group LLC is committed to proactively identifying and mitigating threats before they occur. For more information about Seven Cipher Group LLC, visit www.sevencipher.com.
$KRTL News: KRTL Partnered to Bring Comprehensive Cloud and Endpoint Security and AI Powered Telemedicine Solutions https://finance.yahoo.com/news/krtl-partnered-bring-comprehensive-cloud-130000765.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
$KRTL Axiom utilized the data to complete a full-service package including data acquisition, processing, analysis, technical reporting, and claim management.
$KRTL Medflow, an AI-powered telemedicine solution provider, combines best-in-class facial recognition biometrics with next-generation zero-trust security architecture to accurately verify patient identities. Their comprehensive suite of telemedicine tools, designed with security at the forefront, includes features like end-to-end encryption, facial recognition with ID scan, and HIPAA compliance. The platform allows healthcare providers to review and legally sign medical and legal documentation live with the patient, issue prescriptions, and capture patient vitals such as heart rate, blood pressure, breathing, and stress indicators, all using the patient's computer or mobile phone camera.
https://www.marketwatch.com/press-release/krtl-partnered-to-bring-comprehensive-cloud-and-endpoint-security-and-ai-powered-telemedicine-solutions-2023-05-30?mod=mw_quote_news_seemore
$KRTL entered into a channel partner agreement and white label contract with Medflow Inc. (“Medflow”), creator of a cutting-edge computer-vision based telemedicine platform. This exclusive contract allows KRTL to use and apply Medflow's innovative telemedicine technology in the alternative wellness market.
Medflow, an AI-powered telemedicine solution provider, combines best-in-class facial recognition biometrics with next-generation zero-trust security architecture to accurately verify patient identities. Their comprehensive suite of telemedicine tools, designed with security at the forefront, includes features like end-to-end encryption, facial recognition with ID scan, and HIPAA compliance. The platform allows healthcare providers to review and legally sign medical and legal documentation live with the patient, issue prescriptions, and capture patient vitals such as heart rate, blood pressure, breathing, and stress indicators, all using the patient's computer or mobile phone camera.
Daniel Ball, CEO of KRTL Biotech, is excited about this partnership. He states, "Our collaboration with Medflow is a significant step forward in our mission to enhance patient care in the alternative wellness sector. The integration of Medflow's state-of-the-art telemedicine platform will allow us to provide secure and robust health-related services remotely in the alternative wellness market."
Kelly Fenemore, CEO of Medflow, also shares this enthusiasm. "We are thrilled to partner with KRTL Biotech, a company that shares our commitment to innovation and patient care. This partnership reinforces our mission to provide secure and accessible telemedicine services to patients everywhere."
In a strategic move to bolster its cybersecurity capabilities in support of their MedTech expansion, KRTL Biotech has also entered into a channel partner agreement with boutique cybersecurity firm, Seven Cipher Group LLC ("Seven Cipher"). Seven Cipher combines industry-leading technology and methodology to provide comprehensive cloud and endpoint security solutions. Their innovative approach includes AI, machine learning, and behavioral analytics for proactive threat detection and management.
Seven Cipher’s robust vulnerability assessment and management solutions, along with compliance standards such as ISO, NIST, GDPR, SOC2, and others, will ensure a multi-layered security and compliance approach for KRTL's operations. This partnership will enhance KRTL's ability to safeguard its client’s Web2 and Web3 environments from future threats, including AI-assisted intrusions and eventual quantum-based attacks.
Bryant Thornton, CEO of Seven Cipher, recognizes the significance of this alliance. "Our partnership with KRTL Biotech signals the accessibility and attainability of enterprise-level cybersecurity at a small and medium business level in the alternative wellness industry and beyond. With our combined expertise, we are well-positioned to tackle the unique challenges of this rapidly evolving digital landscape."
"Our partnership with Seven Cipher is crucial in our commitment to provide secure and reliable services in our MedTech efforts alongside solutions like Medflow. As we continue to innovate in our industry, the security of our operations and the privacy of our clients and partners remain a top priority." KRTL Biotech’s CEO, Daniel Ball added.
About KRTL Holding Group, Inc.
KRTL is a holding company interested in diversifying risk and accessing new markets. KRTL Holding Group Inc. operates its wholly owned subsidiaries, KRTL Biotech, Inc. and KRTL International Corp. Each company has its focus on specific industries including bio and Agri-Technology, to International Trade and Distribution of these technologies and services. This strategy allows KRTL Holding Group to capitalize on investment opportunities, and partnerships, creating value for its shareholders. Additional information on KRTL is available online at www.krtlholding.com and www.krtl-icc.com and www.krtlbiotech.com.
About Medflow Inc.
Medflow is a telemedicine company that offers a suite of secure and innovative telemedicine tools. Its offerings include facial recognition biometrics, zero-trust architecture, end-to-end encryption, and a variety of computer vision-based features. These tools allow healthcare providers to offer efficient and secure patient care. For more information about Medflow, visit www.medflow.com.
About Seven Cipher Group LLC
Seven Cipher Group LLC is a boutique cybersecurity firm that offers comprehensive security solutions designed for Web2 and Web3 environments. The company combines industry-leading technology and methodology to offer real-time, comprehensive analysis across your cloud and endpoint security landscape. Seven Cipher Group LLC is committed to proactively identifying and mitigating threats before they occur. For more information about Seven Cipher Group LLC, visit www.sevencipher.com.
$KRTL its wholly owned subsidiary, KRTL Biotech (“KRTL”), has entered into a channel partner agreement and white label contract with Medflow Inc. (“Medflow”), creator of a cutting-edge computer-vision based telemedicine platform. This exclusive contract allows KRTL to use and apply Medflow's innovative telemedicine technology in the alternative wellness market.
Medflow, an AI-powered telemedicine solution provider, combines best-in-class facial recognition biometrics with next-generation zero-trust security architecture to accurately verify patient identities. Their comprehensive suite of telemedicine tools, designed with security at the forefront, includes features like end-to-end encryption, facial recognition with ID scan, and HIPAA compliance. The platform allows healthcare providers to review and legally sign medical and legal documentation live with the patient, issue prescriptions, and capture patient vitals such as heart rate, blood pressure, breathing, and stress indicators, all using the patient's computer or mobile phone camera.
Daniel Ball, CEO of KRTL Biotech, is excited about this partnership. He states, "Our collaboration with Medflow is a significant step forward in our mission to enhance patient care in the alternative wellness sector. The integration of Medflow's state-of-the-art telemedicine platform will allow us to provide secure and robust health-related services remotely in the alternative wellness market."
Kelly Fenemore, CEO of Medflow, also shares this enthusiasm. "We are thrilled to partner with KRTL Biotech, a company that shares our commitment to innovation and patient care. This partnership reinforces our mission to provide secure and accessible telemedicine services to patients everywhere."
In a strategic move to bolster its cybersecurity capabilities in support of their MedTech expansion, KRTL Biotech has also entered into a channel partner agreement with boutique cybersecurity firm, Seven Cipher Group LLC ("Seven Cipher"). Seven Cipher combines industry-leading technology and methodology to provide comprehensive cloud and endpoint security solutions. Their innovative approach includes AI, machine learning, and behavioral analytics for proactive threat detection and management.
Seven Cipher’s robust vulnerability assessment and management solutions, along with compliance standards such as ISO, NIST, GDPR, SOC2, and others, will ensure a multi-layered security and compliance approach for KRTL's operations. This partnership will enhance KRTL's ability to safeguard its client’s Web2 and Web3 environments from future threats, including AI-assisted intrusions and eventual quantum-based attacks.
Bryant Thornton, CEO of Seven Cipher, recognizes the significance of this alliance. "Our partnership with KRTL Biotech signals the accessibility and attainability of enterprise-level cybersecurity at a small and medium business level in the alternative wellness industry and beyond. With our combined expertise, we are well-positioned to tackle the unique challenges of this rapidly evolving digital landscape."
"Our partnership with Seven Cipher is crucial in our commitment to provide secure and reliable services in our MedTech efforts alongside solutions like Medflow. As we continue to innovate in our industry, the security of our operations and the privacy of our clients and partners remain a top priority." KRTL Biotech’s CEO, Daniel Ball added.
About KRTL Holding Group, Inc.
KRTL is a holding company interested in diversifying risk and accessing new markets. KRTL Holding Group Inc. operates its wholly owned subsidiaries, KRTL Biotech, Inc. and KRTL International Corp. Each company has its focus on specific industries including bio and Agri-Technology, to International Trade and Distribution of these technologies and services. This strategy allows KRTL Holding Group to capitalize on investment opportunities, and partnerships, creating value for its shareholders. Additional information on KRTL is available online at www.krtlholding.com and www.krtl-icc.com and www.krtlbiotech.com.
About Medflow Inc.
Medflow is a telemedicine company that offers a suite of secure and innovative telemedicine tools. Its offerings include facial recognition biometrics, zero-trust architecture, end-to-end encryption, and a variety of computer vision-based features. These tools allow healthcare providers to offer efficient and secure patient care. For more information about Medflow, visit www.medflow.com.
About Seven Cipher Group LLC
Seven Cipher Group LLC is a boutique cybersecurity firm that offers comprehensive security solutions designed for Web2 and Web3 environments. The company combines industry-leading technology and methodology to offer real-time, comprehensive analysis across your cloud and endpoint security landscape. Seven Cipher Group LLC is committed to proactively identifying and mitigating threats before they occur. For more information about Seven Cipher Group LLC, visit www.sevencipher.com.
$KRTL May 30, 2023 (GLOBE NEWSWIRE) -- KRTL Holding Group, Inc. (OTC:KRTL), an innovator and pioneer in developing industry-leading cross-over tradecraft and proprietary technology in the hemp, cannabis, psilocybin, and alternative wellness sectors, announces that its wholly owned subsidiary, KRTL Biotech (“KRTL”), has entered into a channel partner agreement and white label contract with Medflow Inc. (“Medflow”), creator of a cutting-edge computer-vision based telemedicine platform. This exclusive contract allows KRTL to use and apply Medflow's innovative telemedicine technology in the alternative wellness market.
Medflow, an AI-powered telemedicine solution provider, combines best-in-class facial recognition biometrics with next-generation zero-trust security architecture to accurately verify patient identities. Their comprehensive suite of telemedicine tools, designed with security at the forefront, includes features like end-to-end encryption, facial recognition with ID scan, and HIPAA compliance. The platform allows healthcare providers to review and legally sign medical and legal documentation live with the patient, issue prescriptions, and capture patient vitals such as heart rate, blood pressure, breathing, and stress indicators, all using the patient's computer or mobile phone camera.
Daniel Ball, CEO of KRTL Biotech, is excited about this partnership. He states, "Our collaboration with Medflow is a significant step forward in our mission to enhance patient care in the alternative wellness sector. The integration of Medflow's state-of-the-art telemedicine platform will allow us to provide secure and robust health-related services remotely in the alternative wellness market."
Kelly Fenemore, CEO of Medflow, also shares this enthusiasm. "We are thrilled to partner with KRTL Biotech, a company that shares our commitment to innovation and patient care. This partnership reinforces our mission to provide secure and accessible telemedicine services to patients everywhere."
In a strategic move to bolster its cybersecurity capabilities in support of their MedTech expansion, KRTL Biotech has also entered into a channel partner agreement with boutique cybersecurity firm, Seven Cipher Group LLC ("Seven Cipher"). Seven Cipher combines industry-leading technology and methodology to provide comprehensive cloud and endpoint security solutions. Their innovative approach includes AI, machine learning, and behavioral analytics for proactive threat detection and management.
Seven Cipher’s robust vulnerability assessment and management solutions, along with compliance standards such as ISO, NIST, GDPR, SOC2, and others, will ensure a multi-layered security and compliance approach for KRTL's operations. This partnership will enhance KRTL's ability to safeguard its client’s Web2 and Web3 environments from future threats, including AI-assisted intrusions and eventual quantum-based attacks.
Bryant Thornton, CEO of Seven Cipher, recognizes the significance of this alliance. "Our partnership with KRTL Biotech signals the accessibility and attainability of enterprise-level cybersecurity at a small and medium business level in the alternative wellness industry and beyond. With our combined expertise, we are well-positioned to tackle the unique challenges of this rapidly evolving digital landscape."
"Our partnership with Seven Cipher is crucial in our commitment to provide secure and reliable services in our MedTech efforts alongside solutions like Medflow. As we continue to innovate in our industry, the security of our operations and the privacy of our clients and partners remain a top priority." KRTL Biotech’s CEO, Daniel Ball added.
About KRTL Holding Group, Inc.
KRTL is a holding company interested in diversifying risk and accessing new markets. KRTL Holding Group Inc. operates its wholly owned subsidiaries, KRTL Biotech, Inc. and KRTL International Corp. Each company has its focus on specific industries including bio and Agri-Technology, to International Trade and Distribution of these technologies and services. This strategy allows KRTL Holding Group to capitalize on investment opportunities, and partnerships, creating value for its shareholders. Additional information on KRTL is available online at www.krtlholding.com and www.krtl-icc.com and www.krtlbiotech.com.
About Medflow Inc.
Medflow is a telemedicine company that offers a suite of secure and innovative telemedicine tools. Its offerings include facial recognition biometrics, zero-trust architecture, end-to-end encryption, and a variety of computer vision-based features. These tools allow healthcare providers to offer efficient and secure patient care. For more information about Medflow, visit www.medflow.com.
About Seven Cipher Group LLC
Seven Cipher Group LLC is a boutique cybersecurity firm that offers comprehensive security solutions designed for Web2 and Web3 environments. The company combines industry-leading technology and methodology to offer real-time, comprehensive analysis across your cloud and endpoint security landscape. Seven Cipher Group LLC is committed to proactively identifying and mitigating threats before they occur. For more information about Seven Cipher Group LLC, visit www.sevencipher.com.
$KRTL agreement and white label contract with Medflow Inc. (“Medflow”), creator of a cutting-edge computer-vision based telemedicine platform. This exclusive contract allows KRTL to use and apply Medflow's innovative telemedicine technology in the alternative wellness market.
Medflow, an AI-powered telemedicine solution provider, combines best-in-class facial recognition biometrics with next-generation zero-trust security architecture to accurately verify patient identities. Their comprehensive suite of telemedicine tools, designed with security at the forefront, includes features like end-to-end encryption, facial recognition with ID scan, and HIPAA compliance. The platform allows healthcare providers to review and legally sign medical and legal documentation live with the patient, issue prescriptions, and capture patient vitals such as heart rate, blood pressure, breathing, and stress indicators, all using the patient's computer or mobile phone camera.
Daniel Ball, CEO of KRTL Biotech, is excited about this partnership. He states, "Our collaboration with Medflow is a significant step forward in our mission to enhance patient care in the alternative wellness sector. The integration of Medflow's state-of-the-art telemedicine platform will allow us to provide secure and robust health-related services remotely in the alternative wellness market."
Kelly Fenemore, CEO of Medflow, also shares this enthusiasm. "We are thrilled to partner with KRTL Biotech, a company that shares our commitment to innovation and patient care. This partnership reinforces our mission to provide secure and accessible telemedicine services to patients everywhere."
In a strategic move to bolster its cybersecurity capabilities in support of their MedTech expansion, KRTL Biotech has also entered into a channel partner agreement with boutique cybersecurity firm, Seven Cipher Group LLC ("Seven Cipher"). Seven Cipher combines industry-leading technology and methodology to provide comprehensive cloud and endpoint security solutions. Their innovative approach includes AI, machine learning, and behavioral analytics for proactive threat detection and management.
Seven Cipher’s robust vulnerability assessment and management solutions, along with compliance standards such as ISO, NIST, GDPR, SOC2, and others, will ensure a multi-layered security and compliance approach for KRTL's operations. This partnership will enhance KRTL's ability to safeguard its client’s Web2 and Web3 environments from future threats, including AI-assisted intrusions and eventual quantum-based attacks.
Bryant Thornton, CEO of Seven Cipher, recognizes the significance of this alliance. "Our partnership with KRTL Biotech signals the accessibility and attainability of enterprise-level cybersecurity at a small and medium business level in the alternative wellness industry and beyond. With our combined expertise, we are well-positioned to tackle the unique challenges of this rapidly evolving digital landscape."
"Our partnership with Seven Cipher is crucial in our commitment to provide secure and reliable services in our MedTech efforts alongside solutions like Medflow. As we continue to innovate in our industry, the security of our operations and the privacy of our clients and partners remain a top priority." KRTL Biotech’s CEO, Daniel Ball added.
About KRTL Holding Group, Inc.
KRTL is a holding company interested in diversifying risk and accessing new markets. KRTL Holding Group Inc. operates its wholly owned subsidiaries, KRTL Biotech, Inc. and KRTL International Corp. Each company has its focus on specific industries including bio and Agri-Technology, to International Trade and Distribution of these technologies and services. This strategy allows KRTL Holding Group to capitalize on investment opportunities, and partnerships, creating value for its shareholders. Additional information on KRTL is available online at www.krtlholding.com and www.krtl-icc.com and www.krtlbiotech.com.
About Medflow Inc.
Medflow is a telemedicine company that offers a suite of secure and innovative telemedicine tools. Its offerings include facial recognition biometrics, zero-trust architecture, end-to-end encryption, and a variety of computer vision-based features. These tools allow healthcare providers to offer efficient and secure patient care. For more information about Medflow, visit www.medflow.com.
About Seven Cipher Group LLC
Seven Cipher Group LLC is a boutique cybersecurity firm that offers comprehensive security solutions designed for Web2 and Web3 environments. The company combines industry-leading technology and methodology to offer real-time, comprehensive analysis across your cloud and endpoint security landscape. Seven Cipher Group LLC is committed to proactively identifying and mitigating threats before they occur. For more information about Seven Cipher Group LLC, visit www.sevencipher.com.
$KRTL KRTL Biotech (“KRTL”), has entered into a channel partner agreement and white label contract with Medflow Inc. (“Medflow”), creator of a cutting-edge computer-vision based telemedicine platform. This exclusive contract allows KRTL to use and apply Medflow's innovative telemedicine technology in the alternative wellness market.
Medflow, an AI-powered telemedicine solution provider, combines best-in-class facial recognition biometrics with next-generation zero-trust security architecture to accurately verify patient identities. Their comprehensive suite of telemedicine tools, designed with security at the forefront, includes features like end-to-end encryption, facial recognition with ID scan, and HIPAA compliance. The platform allows healthcare providers to review and legally sign medical and legal documentation live with the patient, issue prescriptions, and capture patient vitals such as heart rate, blood pressure, breathing, and stress indicators, all using the patient's computer or mobile phone camera.
Daniel Ball, CEO of KRTL Biotech, is excited about this partnership. He states, "Our collaboration with Medflow is a significant step forward in our mission to enhance patient care in the alternative wellness sector. The integration of Medflow's state-of-the-art telemedicine platform will allow us to provide secure and robust health-related services remotely in the alternative wellness market."
Kelly Fenemore, CEO of Medflow, also shares this enthusiasm. "We are thrilled to partner with KRTL Biotech, a company that shares our commitment to innovation and patient care. This partnership reinforces our mission to provide secure and accessible telemedicine services to patients everywhere."
In a strategic move to bolster its cybersecurity capabilities in support of their MedTech expansion, KRTL Biotech has also entered into a channel partner agreement with boutique cybersecurity firm, Seven Cipher Group LLC ("Seven Cipher"). Seven Cipher combines industry-leading technology and methodology to provide comprehensive cloud and endpoint security solutions. Their innovative approach includes AI, machine learning, and behavioral analytics for proactive threat detection and management.
Seven Cipher’s robust vulnerability assessment and management solutions, along with compliance standards such as ISO, NIST, GDPR, SOC2, and others, will ensure a multi-layered security and compliance approach for KRTL's operations. This partnership will enhance KRTL's ability to safeguard its client’s Web2 and Web3 environments from future threats, including AI-assisted intrusions and eventual quantum-based attacks.
Bryant Thornton, CEO of Seven Cipher, recognizes the significance of this alliance. "Our partnership with KRTL Biotech signals the accessibility and attainability of enterprise-level cybersecurity at a small and medium business level in the alternative wellness industry and beyond. With our combined expertise, we are well-positioned to tackle the unique challenges of this rapidly evolving digital landscape."
"Our partnership with Seven Cipher is crucial in our commitment to provide secure and reliable services in our MedTech efforts alongside solutions like Medflow. As we continue to innovate in our industry, the security of our operations and the privacy of our clients and partners remain a top priority." KRTL Biotech’s CEO, Daniel Ball added.
About KRTL Holding Group, Inc.
KRTL is a holding company interested in diversifying risk and accessing new markets. KRTL Holding Group Inc. operates its wholly owned subsidiaries, KRTL Biotech, Inc. and KRTL International Corp. Each company has its focus on specific industries including bio and Agri-Technology, to International Trade and Distribution of these technologies and services. This strategy allows KRTL Holding Group to capitalize on investment opportunities, and partnerships, creating value for its shareholders. Additional information on KRTL is available online at www.krtlholding.com and www.krtl-icc.com and www.krtlbiotech.com.
About Medflow Inc.
Medflow is a telemedicine company that offers a suite of secure and innovative telemedicine tools. Its offerings include facial recognition biometrics, zero-trust architecture, end-to-end encryption, and a variety of computer vision-based features. These tools allow healthcare providers to offer efficient and secure patient care. For more information about Medflow, visit www.medflow.com.
About Seven Cipher Group LLC
Seven Cipher Group LLC is a boutique cybersecurity firm that offers comprehensive security solutions designed for Web2 and Web3 environments. The company combines industry-leading technology and methodology to offer real-time, comprehensive analysis across your cloud and endpoint security landscape. Seven Cipher Group LLC is committed to proactively identifying and mitigating threats before they occur. For more information about Seven Cipher Group LLC, visit www.sevencipher.com.
$KRTL (GLOBE NEWSWIRE) -- KRTL Holding Group, Inc. (OTC:KRTL), an innovator and pioneer in developing industry-leading cross-over tradecraft and proprietary technology in the hemp, cannabis, psilocybin, and alternative wellness sectors, announces that its wholly owned subsidiary, KRTL Biotech (“KRTL”), has entered into a channel partner agreement and white label contract with Medflow Inc. (“Medflow”), creator of a cutting-edge computer-vision based telemedicine platform. This exclusive contract allows KRTL to use and apply Medflow's innovative telemedicine technology in the alternative wellness market.
Medflow, an AI-powered telemedicine solution provider, combines best-in-class facial recognition biometrics with next-generation zero-trust security architecture to accurately verify patient identities. Their comprehensive suite of telemedicine tools, designed with security at the forefront, includes features like end-to-end encryption, facial recognition with ID scan, and HIPAA compliance. The platform allows healthcare providers to review and legally sign medical and legal documentation live with the patient, issue prescriptions, and capture patient vitals such as heart rate, blood pressure, breathing, and stress indicators, all using the patient's computer or mobile phone camera.
Daniel Ball, CEO of KRTL Biotech, is excited about this partnership. He states, "Our collaboration with Medflow is a significant step forward in our mission to enhance patient care in the alternative wellness sector. The integration of Medflow's state-of-the-art telemedicine platform will allow us to provide secure and robust health-related services remotely in the alternative wellness market."
Kelly Fenemore, CEO of Medflow, also shares this enthusiasm. "We are thrilled to partner with KRTL Biotech, a company that shares our commitment to innovation and patient care. This partnership reinforces our mission to provide secure and accessible telemedicine services to patients everywhere."
In a strategic move to bolster its cybersecurity capabilities in support of their MedTech expansion, KRTL Biotech has also entered into a channel partner agreement with boutique cybersecurity firm, Seven Cipher Group LLC ("Seven Cipher"). Seven Cipher combines industry-leading technology and methodology to provide comprehensive cloud and endpoint security solutions. Their innovative approach includes AI, machine learning, and behavioral analytics for proactive threat detection and management.
Seven Cipher’s robust vulnerability assessment and management solutions, along with compliance standards such as ISO, NIST, GDPR, SOC2, and others, will ensure a multi-layered security and compliance approach for KRTL's operations. This partnership will enhance KRTL's ability to safeguard its client’s Web2 and Web3 environments from future threats, including AI-assisted intrusions and eventual quantum-based attacks.
Bryant Thornton, CEO of Seven Cipher, recognizes the significance of this alliance. "Our partnership with KRTL Biotech signals the accessibility and attainability of enterprise-level cybersecurity at a small and medium business level in the alternative wellness industry and beyond. With our combined expertise, we are well-positioned to tackle the unique challenges of this rapidly evolving digital landscape."
"Our partnership with Seven Cipher is crucial in our commitment to provide secure and reliable services in our MedTech efforts alongside solutions like Medflow. As we continue to innovate in our industry, the security of our operations and the privacy of our clients and partners remain a top priority." KRTL Biotech’s CEO, Daniel Ball added.
About KRTL Holding Group, Inc.
KRTL is a holding company interested in diversifying risk and accessing new markets. KRTL Holding Group Inc. operates its wholly owned subsidiaries, KRTL Biotech, Inc. and KRTL International Corp. Each company has its focus on specific industries including bio and Agri-Technology, to International Trade and Distribution of these technologies and services. This strategy allows KRTL Holding Group to capitalize on investment opportunities, and partnerships, creating value for its shareholders. Additional information on KRTL is available online at www.krtlholding.com and www.krtl-icc.com and www.krtlbiotech.com.
About Medflow Inc.
Medflow is a telemedicine company that offers a suite of secure and innovative telemedicine tools. Its offerings include facial recognition biometrics, zero-trust architecture, end-to-end encryption, and a variety of computer vision-based features. These tools allow healthcare providers to offer efficient and secure patient care. For more information about Medflow, visit www.medflow.com.
About Seven Cipher Group LLC
Seven Cipher Group LLC is a boutique cybersecurity firm that offers comprehensive security solutions designed for Web2 and Web3 environments. The company combines industry-leading technology and methodology to offer real-time, comprehensive analysis across your cloud and endpoint security landscape. Seven Cipher Group LLC is committed to proactively identifying and mitigating threats before they occur. For more information about Seven Cipher Group LLC, visit www.sevencipher.com.
$KRTL Axiom utilized the data to complete a full-service package including data acquisition, processing, analysis, technical reporting, and claim management.
$KRTL Seven Cipher’s robust vulnerability assessment and management solutions, along with compliance standards such as ISO, NIST, GDPR, SOC2, and others, will ensure a multi-layered security and compliance approach for KRTL's operations. This partnership will enhance KRTL's ability to safeguard its client’s Web2 and Web3 environments from future threats, including AI-assisted intrusions and eventual quantum-based attacks.
https://www.barrons.com/articles/krtl-partnered-to-bring-comprehensive-cloud-and-endpoint-security-and-ai-powered-telemedicine-solutions-eaa82e6d?mod=md_stockoverview_news
$KRTL $MMMW pioneering innovation. Please check them out.
$KRTL Medflow, an AI-powered telemedicine solution provider, combines best-in-class facial recognition biometrics with next-generation zero-trust security architecture to accurately verify patient identities. Their comprehensive suite of telemedicine tools, designed with security at the forefront, includes features like end-to-end encryption, facial recognition with ID scan, and HIPAA compliance. The platform allows healthcare providers to review and legally sign medical and legal documentation live with the patient, issue prescriptions, and capture patient vitals such as heart rate, blood pressure, breathing, and stress indicators, all using the patient's computer or mobile phone camera.
https://www.marketwatch.com/press-release/krtl-partnered-to-bring-comprehensive-cloud-and-endpoint-security-and-ai-powered-telemedicine-solutions-2023-05-30?mod=mw_quote_news_seemore
$KRTL The Company Partnered to Bring Comprehensive Cloud and Endpoint Security and AI Powered Telemedicine Solutions https://finance.yahoo.com/news/krtl-partnered-bring-comprehensive-cloud-130000765.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
$KRTL Kelly Fenemore, CEO of Medflow, also shares this enthusiasm. "We are thrilled to partner with KRTL Biotech, a company that shares our commitment to innovation and patient care. This partnership reinforces our mission to provide secure and accessible telemedicine services to patients everywhere."
In a strategic move to bolster its cybersecurity capabilities in support of their MedTech expansion, KRTL Biotech has also entered into a channel partner agreement with boutique cybersecurity firm, Seven Cipher Group LLC ("Seven Cipher"). Seven Cipher combines industry-leading technology and methodology to provide comprehensive cloud and endpoint security solutions. Their innovative approach includes AI, machine learning, and behavioral analytics for proactive threat detection and management.
Seven Cipher’s robust vulnerability assessment and management solutions, along with compliance standards such as ISO, NIST, GDPR, SOC2, and others, will ensure a multi-layered security and compliance approach for KRTL's operations. This partnership will enhance KRTL's ability to safeguard its client’s Web2 and Web3 environments from future threats, including AI-assisted intrusions and eventual quantum-based attacks.
Bryant Thornton, CEO of Seven Cipher, recognizes the significance of this alliance. "Our partnership with KRTL Biotech signals the accessibility and attainability of enterprise-level cybersecurity at a small and medium business level in the alternative wellness industry and beyond. With our combined expertise, we are well-positioned to tackle the unique challenges of this rapidly evolving digital landscape."
"Our partnership with Seven Cipher is crucial in our commitment to provide secure and reliable services in our MedTech efforts alongside solutions like Medflow. As we continue to innovate in our industry, the security of our operations and the privacy of our clients and partners remain a top priority." KRTL Biotech’s CEO, Daniel Ball added.
About KRTL Holding Group, Inc.
KRTL is a holding company interested in diversifying risk and accessing new markets. KRTL Holding Group Inc. operates its wholly owned subsidiaries, KRTL Biotech, Inc. and KRTL International Corp. Each company has its focus on specific industries including bio and Agri-Technology, to International Trade and Distribution of these technologies and services. This strategy allows KRTL Holding Group to capitalize on investment opportunities, and partnerships, creating value for its shareholders. Additional information on KRTL is available online at www.krtlholding.com and www.krtl-icc.com and www.krtlbiotech.com.
$KRTL cross-over tradecraft and proprietary technology in the hemp, cannabis, psilocybin, and alternative wellness sectors, announces that its wholly owned subsidiary, KRTL Biotech (“KRTL”), has entered into a channel partner agreement and white label contract with Medflow Inc. (“Medflow”), creator of a cutting-edge computer-vision based telemedicine platform. This exclusive contract allows KRTL to use and apply Medflow's innovative telemedicine technology in the alternative wellness market.
Medflow, an AI-powered telemedicine solution provider, combines best-in-class facial recognition biometrics with next-generation zero-trust security architecture to accurately verify patient identities. Their comprehensive suite of telemedicine tools, designed with security at the forefront, includes features like end-to-end encryption, facial recognition with ID scan, and HIPAA compliance. The platform allows healthcare providers to review and legally sign medical and legal documentation live with the patient, issue prescriptions, and capture patient vitals such as heart rate, blood pressure, breathing, and stress indicators, all using the patient's computer or mobile phone camera.
Daniel Ball, CEO of KRTL Biotech, is excited about this partnership. He states, "Our collaboration with Medflow is a significant step forward in our mission to enhance patient care in the alternative wellness sector. The integration of Medflow's state-of-the-art telemedicine platform will allow us to provide secure and robust health-related services remotely in the alternative wellness market."
Kelly Fenemore, CEO of Medflow, also shares this enthusiasm. "We are thrilled to partner with KRTL Biotech, a company that shares our commitment to innovation and patient care. This partnership reinforces our mission to provide secure and accessible telemedicine services to patients everywhere."
In a strategic move to bolster its cybersecurity capabilities in support of their MedTech expansion, KRTL Biotech has also entered into a channel partner agreement with boutique cybersecurity firm, Seven Cipher Group LLC ("Seven Cipher"). Seven Cipher combines industry-leading technology and methodology to provide comprehensive cloud and endpoint security solutions. Their innovative approach includes AI, machine learning, and behavioral analytics for proactive threat detection and management.
Seven Cipher’s robust vulnerability assessment and management solutions, along with compliance standards such as ISO, NIST, GDPR, SOC2, and others, will ensure a multi-layered security and compliance approach for KRTL's operations. This partnership will enhance KRTL's ability to safeguard its client’s Web2 and Web3 environments from future threats, including AI-assisted intrusions and eventual quantum-based attacks.
Bryant Thornton, CEO of Seven Cipher, recognizes the significance of this alliance. "Our partnership with KRTL Biotech signals the accessibility and attainability of enterprise-level cybersecurity at a small and medium business level in the alternative wellness industry and beyond. With our combined expertise, we are well-positioned to tackle the unique challenges of this rapidly evolving digital landscape."
"Our partnership with Seven Cipher is crucial in our commitment to provide secure and reliable services in our MedTech efforts alongside solutions like Medflow. As we continue to innovate in our industry, the security of our operations and the privacy of our clients and partners remain a top priority." KRTL Biotech’s CEO, Daniel Ball added.
About KRTL Holding Group, Inc.
KRTL is a holding company interested in diversifying risk and accessing new markets. KRTL Holding Group Inc. operates its wholly owned subsidiaries, KRTL Biotech, Inc. and KRTL International Corp. Each company has its focus on specific industries including bio and Agri-Technology, to International Trade and Distribution of these technologies and services. This strategy allows KRTL Holding Group to capitalize on investment opportunities, and partnerships, creating value for its shareholders. Additional information on KRTL is available online at www.krtlholding.com and www.krtl-icc.com and www.krtlbiotech.com.
$DTII news and $MMMW news today.
$KRTL Seven Cipher Group LLC is a boutique cybersecurity firm that offers comprehensive security solutions designed for Web2 and Web3 environments. The company combines industry-leading technology and methodology to offer real-time, comprehensive analysis across your cloud and endpoint security landscape. Seven Cipher Group LLC is committed to proactively identifying and mitigating threats before they occur. For more information about Seven Cipher Group LLC, visit www.sevencipher.com.
$KRTL's strategic move to bolster its cybersecurity capabilities in support of their MedTech expansion, KRTL Biotech has also entered into a channel partner agreement with boutique cybersecurity firm, Seven Cipher Group LLC ("Seven Cipher"). Seven Cipher combines industry-leading technology and methodology to provide comprehensive cloud and endpoint security solutions. Their innovative approach includes AI, machine learning, and behavioral analytics for proactive threat detection and management.
https://www.morningstar.com/news/globe-newswire/8847936/krtl-partnered-to-bring-comprehensive-cloud-and-endpoint-security-and-ai-powered-telemedicine-solutions
$KRTL (OTC:KRTL), an innovator and pioneer in developing industry-leading cross-over tradecraft and proprietary technology in the hemp, cannabis, psilocybin, and alternative wellness sectors, announces that its wholly owned subsidiary, KRTL Biotech (“KRTL”), has entered into a channel partner agreement and white label contract with Medflow Inc. (“Medflow”), creator of a cutting-edge computer-vision based telemedicine platform. This exclusive contract allows KRTL to use and apply Medflow's innovative telemedicine technology in the alternative wellness market.
Medflow, an AI-powered telemedicine solution provider, combines best-in-class facial recognition biometrics with next-generation zero-trust security architecture to accurately verify patient identities. Their comprehensive suite of telemedicine tools, designed with security at the forefront, includes features like end-to-end encryption, facial recognition with ID scan, and HIPAA compliance. The platform allows healthcare providers to review and legally sign medical and legal documentation live with the patient, issue prescriptions, and capture patient vitals such as heart rate, blood pressure, breathing, and stress indicators, all using the patient's computer or mobile phone camera.
Daniel Ball, CEO of KRTL Biotech, is excited about this partnership. He states, "Our collaboration with Medflow is a significant step forward in our mission to enhance patient care in the alternative wellness sector. The integration of Medflow's state-of-the-art telemedicine platform will allow us to provide secure and robust health-related services remotely in the alternative wellness market."
Kelly Fenemore, CEO of Medflow, also shares this enthusiasm. "We are thrilled to partner with KRTL Biotech, a company that shares our commitment to innovation and patient care. This partnership reinforces our mission to provide secure and accessible telemedicine services to patients everywhere."
In a strategic move to bolster its cybersecurity capabilities in support of their MedTech expansion, KRTL Biotech has also entered into a channel partner agreement with boutique cybersecurity firm, Seven Cipher Group LLC ("Seven Cipher"). Seven Cipher combines industry-leading technology and methodology to provide comprehensive cloud and endpoint security solutions. Their innovative approach includes AI, machine learning, and behavioral analytics for proactive threat detection and management.
Seven Cipher’s robust vulnerability assessment and management solutions, along with compliance standards such as ISO, NIST, GDPR, SOC2, and others, will ensure a multi-layered security and compliance approach for KRTL's operations. This partnership will enhance KRTL's ability to safeguard its client’s Web2 and Web3 environments from future threats, including AI-assisted intrusions and eventual quantum-based attacks.
Bryant Thornton, CEO of Seven Cipher, recognizes the significance of this alliance. "Our partnership with KRTL Biotech signals the accessibility and attainability of enterprise-level cybersecurity at a small and medium business level in the alternative wellness industry and beyond. With our combined expertise, we are well-positioned to tackle the unique challenges of this rapidly evolving digital landscape."
"Our partnership with Seven Cipher is crucial in our commitment to provide secure and reliable services in our MedTech efforts alongside solutions like Medflow. As we continue to innovate in our industry, the security of our operations and the privacy of our clients and partners remain a top priority." KRTL Biotech’s CEO, Daniel Ball added.
About KRTL Holding Group, Inc.
KRTL is a holding company interested in diversifying risk and accessing new markets. KRTL Holding Group Inc. operates its wholly owned subsidiaries, KRTL Biotech, Inc. and KRTL International Corp. Each company has its focus on specific industries including bio and Agri-Technology, to International Trade and Distribution of these technologies and services. This strategy allows KRTL Holding Group to capitalize on investment opportunities, and partnerships, creating value for its shareholders. Additional information on KRTL is available online at www.krtlholding.com and www.krtl-icc.com and www.krtlbiotech.com.
$KRTL Axiom utilized the data to complete a full-service package including data acquisition, processing, analysis, technical reporting, and claim management.
$KAVL Kaival Brands Appoints New Independent Member to its Board of Directors
https://www.globenewswire.com/news-release/2023/06/07/2683739/0/en/Kaival-Brands-Appoints-New-Independent-Member-to-its-Board-of-Directors.html
Followers
|
928
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
216694
|
Created
|
07/22/10
|
Type
|
Free
|
Moderator jedijazz | |||
Assistants ProfitScout |
Posts Today
|
0
|
Posts (Total)
|
216694
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |